Unilateral Renal Artery Stenosis With New Proteinuria: Start the ACE Inhibitor, or Avoid It
A single patient with unilateral renal artery stenosis and new proteinuria who needs a RAAS inhibitor for exactly what his kidneys can no longer be assumed to tolerate without watching closely. The disagreement is whether the anatomic risk should be avoided or simply monitored.
Frank O. has managed hypertension for twenty years without much difficulty, on amlodipine alone for most of that time, and was surprised when a routine screening urinalysis at his annual physical came back with new protein that hadn't been there the year before. The workup that followed found 70% stenosis of his right renal artery — unilateral, with a normal-sized, normally functioning contralateral kidney and no solitary-kidney anatomy — incidental to the actual reason he was there, which was blood pressure still running at 158/92 despite his current regimen. His creatinine has been stable at 1.0 for the two years it's been checked.
CORAL is the trial that actually speaks to what happens when RAAS blockade meets renal artery stenosis in practice, even though it was designed to test revascularization, not RAAS inhibitors specifically: adding stenting to optimal medical therapy showed no benefit over medical therapy alone, and that medical-therapy arm — which included ACE inhibitors or ARBs in most enrolled patients — achieved reasonable blood pressure and renal outcomes without needing the procedure. That's useful, indirect evidence that RAAS blockade is generally safe and effective in appropriately selected renal artery stenosis, but it doesn't erase the real physiologic risk that makes this a genuine question rather than a formality: RAAS inhibitors dilate the efferent arteriole, and in bilateral disease or a solitary stenotic kidney, that can drop glomerular filtration precipitously by removing the pressure gradient the stenotic kidney depends on. His anatomy — unilateral, with a normal contralateral kidney able to compensate — is a materially lower-risk scenario than that classic contraindication, though a real minority of even unilateral patients still show a meaningful creatinine rise once treated. His new proteinuria is its own separate reason a RAAS inhibitor is indicated, independent of whatever the renal artery question decides — which is part of what makes simply avoiding the drug class the less obviously conservative choice than it might first appear.
In clinic, after the renal artery imaging came back
His stenosis is unilateral, his contralateral kidney is normal, and CORAL's own medical-therapy arm shows RAAS blockade works fine in appropriately selected renal artery stenosis without needing revascularization. He also has new proteinuria, which is its own reason to start an ACE inhibitor regardless of the renal artery finding. I'd start it.
I'd be more cautious. Even in unilateral disease, a real minority of patients get a meaningful GFR drop once you disrupt the stenotic kidney's renin-dependent perfusion. He's seventy-four, and we don't have a monitoring plan in place yet. I'd add a thiazide instead — effective for his blood pressure, and it sidesteps the anatomic risk entirely.
A thiazide gets his blood pressure down, but it does nothing for the proteinuria — that's a separate problem this approach leaves untreated.
I don't think we need to choose between starting blind and avoiding the class entirely. Start the ACE inhibitor at a low dose, but build the monitoring plan into the prescription itself — creatinine and potassium rechecked at one to two weeks, not at his next routine visit.
If his creatinine rises meaningfully, we'll know within two weeks and can stop the drug before any lasting harm — that's a real, reversible signal, not a silent one. If it doesn't rise, he gets the antiproteinuric benefit his new finding actually calls for. That captures what both of you are right about without treating this as all-or-nothing.
Agreed: start low-dose lisinopril with creatinine and potassium rechecked at one to two weeks, and again at one month. Amlodipine continues unchanged in the interim.
Continue and up-titrate lisinopril as tolerated for both blood pressure and proteinuria control.
Stop the ACE inhibitor and switch to chlorthalidone for blood pressure; revisit renal artery imaging and revascularization discussion separately.